First Tracks Biotherapeutics to release Phase 1b cohort 1 data for ANB033 in celiac disease Oct. 12
TRAX•First Tracks Biotherapeutics plans to release top-line Cohort 1 results from its Phase 1b ANB033 celiac disease trial on Oct. 12, 2026, after a gluten-challenge study assessing whether the drug can prevent intestinal tissue damage.
1. Data release planned
First Tracks Biotherapeutics plans to issue a morning press release with the results on Oct. 12, 2026, followed by an investor call and webcast. Cohort 1 is a gluten-challenge study assessing whether ANB033, a CD122 antagonist being developed for celiac disease, can prevent intestinal tissue damage.
